Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor

PURPOSE: Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and a model of targeted molecular therapy. GIST depends on oncogenic KIT signaling and responds to the tyrosine kinase inhibitor imatinib. However, imatinib is rarely curative. We hypothesized that PLX3397, which inhibit...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Kim, Teresa S., Cavnar, Michael J., Cohen, Noah A., Sorenson, Eric C., Greer, Jonathan B., Seifert, Adrian M., Crawley, Megan H., Green, Benjamin L., Popow, Rachel, Pillarsetty, Nagavarakishore, Veach, Darren R., Ku, Anson T., Rossi, Ferdinand, Besmer, Peter, Antonescu, Cristina R., Zeng, Shan, DeMatteo, Ronald P.
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008656/
https://ncbi.nlm.nih.gov/pubmed/24583793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3033
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы